Ono Pharmaceutical Co. Ltd. has patented tricyclic prostaglandin E2 receptor EP3 subtype (PTGER3; EP3) agonists potentially useful for the treatment of renal diseases.
Researchers from Renmin Hospital of Wuhan University have assessed the role of ankyrin repeat domain 1 (ANKRD1) in renal ischemia-reperfusion injury (IRI), which is the primary cause of acute kidney injury (AKI).
Harbin Medisan Pharmaceutical Co. Ltd. has synthesized PPARδ agonists reported to be useful for the treatment of fibrosis, neurodegeneration, inflammation, cardiovascular, cerebrovascular, autoimmune and metabolic disorders.
Researchers from Japan Tobacco Inc. presented the discovery and preclinical characterization of novel highly potent Keap1-Nrf2 protein-protein interaction (PPI) inhibitors.
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
With full approval from the U.S. FDA in hand for Travere Therapeutics Inc.’s Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression, eyes turned to future prospects as well as how a revised risk evaluation and mitigation strategies (REMS) program might shake out. During a conference call hosted by Travere, Leerink analyst Joseph Schwartz wanted to know what changes might be made, and if the regulator’s decision might “actually be an entire removal” of the REMS.
Recent research indicates that CDC42 plays a role in the pathogenesis of kidney disorders such as congenital nephrotic syndrome or glomerulosclerosis because it is necessary for the correct function of renal podocyte and tubule.
Recent findings suggest gut microbiota dysbiosis may be behind the inflammation in diabetic nephropathy (DN), the leading cause of end-stage renal disease (ESRD).
Shanghai Micurx Pharmaceutical Co. Ltd. has discovered peptide-drug conjugates consisting of peptide-targeting kidney cells covalently linked to anti-inflammatory or immunomodulating or nephron-protective drugs through linkers reported to be useful for the treatment of acute kidney injury, nephritis, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
Acute kidney injury (AKI) is a common disease with high morbidity that still lacks effective drug treatments. The death of tubular epithelial cells is the principal basis for AKI. This cell death in AKI does not occur by necrosis but by other cell death mechanisms such as pyroptosis, among others. Recent findings have implicated chromodomain Y-like (CDYL) in autosomal dominant polycystic kidney disease, but its role in AKI has not been established.
RSS
